25 XP   0   0   10

Cns Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Cns Pharmaceuticals Inc together

PenkeI guess you are interested in Cns Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cns Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cns Pharmaceuticals Inc

I send you an email if I find something interesting about Cns Pharmaceuticals Inc.

Quick analysis of Cns Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Cns Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.53
Expected worth in 1 year
$-1.47
How sure are you?
21.7%

+ What do you gain per year?

Total Gains per Share
$-0.94
Return On Investment
-472.1%

For what price can you sell your share?

Current Price per Share
$0.20
Expected price per share
$0 - $0.321
How sure are you?
50%

1. Valuation of Cns Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$0.20

Intrinsic Value Per Share

$-6.88 - $-7.64

Total Value Per Share

$-7.40 - $-8.16

2. Growth of Cns Pharmaceuticals Inc (5 min.)




Is Cns Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$4.4m$7.8m-$9.9m-487.0%

How much money is Cns Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$4.8m-$4.3m-$464.3k-9.6%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Cns Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#921 / 1011

Most Revenue
#980 / 1011

Most Profit
#415 / 1011

Most Efficient
#423 / 1011

What can you expect buying and holding a share of Cns Pharmaceuticals Inc? (5 min.)

Welcome investor! Cns Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Cns Pharmaceuticals Inc.

What can you expect buying and holding a share of Cns Pharmaceuticals Inc?

First you should know what it really means to hold a share of Cns Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Cns Pharmaceuticals Inc is $0.1991. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cns Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cns Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.53. Based on the TTM, the Book Value Change Per Share is $-0.23 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.34 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cns Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.64-320.2%-0.57-287.4%-0.45-223.8%-0.38-191.4%-0.35-176.4%
Usd Book Value Change Per Share0.000.0%-0.23-118.0%-0.34-168.5%-0.02-11.1%-0.02-11.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%-0.23-118.0%-0.34-168.5%-0.02-11.1%-0.02-11.5%
Usd Price Per Share0.36-1.25-0.96-1.37-1.19-
Price to Earnings Ratio-0.14--0.58--0.51--0.95--0.82-
Price-to-Total Gains Ratio-8.13--20.15--7.58--7.58-
Price to Book Ratio-0.69--0.24-1.32-1.46-1.27-
Price-to-Total Gains Ratio-8.13--20.15--7.58--7.58-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.1991
Number of shares5022
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.23-0.02
Usd Total Gains Per Share-0.23-0.02
Gains per Quarter (5022 shares)-1,180.10-110.66
Gains per Year (5022 shares)-4,720.38-442.65
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-4720-47300-443-453
20-9441-94500-885-896
30-14161-141700-1328-1339
40-18882-188900-1771-1782
50-23602-236100-2213-2225
60-28322-283300-2656-2668
70-33043-330500-3099-3111
80-37763-377700-3541-3554
90-42483-424900-3984-3997
100-47204-472100-4427-4440

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.023.00.00.0%0.023.00.00.0%
Book Value Change Per Share0.03.01.00.0%2.09.01.016.7%5.014.01.025.0%5.016.02.021.7%5.016.02.021.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.023.00.0%0.00.023.00.0%
Total Gains per Share0.03.01.00.0%2.09.01.016.7%5.014.01.025.0%5.016.02.021.7%5.016.02.021.7%

Fundamentals of Cns Pharmaceuticals Inc

About Cns Pharmaceuticals Inc

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Fundamental data was last updated by Penke on 2024-04-11 04:37:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cns Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cns Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cns Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cns Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--196.1%+196.1%
TTM--211.9%+211.9%
YOY--277.7%+277.7%
5Y--432.9%+432.9%
10Y--599.3%+599.3%
1.1.2. Return on Assets

Shows how efficient Cns Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cns Pharmaceuticals Inc to the Biotechnology industry mean.
  • -316.0% Return on Assets means that Cns Pharmaceuticals Inc generated $-3.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cns Pharmaceuticals Inc:

  • The MRQ is -316.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -222.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-316.0%TTM-222.2%-93.9%
TTM-222.2%YOY-43.2%-178.9%
TTM-222.2%5Y-74.4%-147.8%
5Y-74.4%10Y-109.8%+35.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-316.0%-13.3%-302.7%
TTM-222.2%-12.7%-209.5%
YOY-43.2%-11.8%-31.4%
5Y-74.4%-14.0%-60.4%
10Y-109.8%-15.9%-93.9%
1.1.3. Return on Equity

Shows how efficient Cns Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cns Pharmaceuticals Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Cns Pharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cns Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-41.0%+41.0%
TTM-41.0%YOY-70.2%+29.3%
TTM-41.0%5Y-16,405.8%+16,364.8%
5Y-16,405.8%10Y-14,265.9%-2,139.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM-41.0%-16.0%-25.0%
YOY-70.2%-15.1%-55.1%
5Y-16,405.8%-19.7%-16,386.1%
10Y-14,265.9%-20.5%-14,245.4%

1.2. Operating Efficiency of Cns Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cns Pharmaceuticals Inc is operating .

  • Measures how much profit Cns Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cns Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cns Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--290.9%+290.9%
TTM--224.4%+224.4%
YOY--288.3%+288.3%
5Y--479.5%+479.5%
10Y--625.2%+625.2%
1.2.2. Operating Ratio

Measures how efficient Cns Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cns Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.110-3.110
TTM-3.266-3.266
YOY-3.783-3.783
5Y-5.657-5.657
10Y-7.783-7.783

1.3. Liquidity of Cns Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cns Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.23 means the company has $0.23 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cns Pharmaceuticals Inc:

  • The MRQ is 0.226. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.628. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.226TTM0.628-0.401
TTM0.628YOY5.915-5.287
TTM0.6285Y6.833-6.205
5Y6.83310Y5.998+0.834
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2263.905-3.679
TTM0.6284.212-3.584
YOY5.9155.337+0.578
5Y6.8336.062+0.771
10Y5.9986.401-0.403
1.3.2. Quick Ratio

Measures if Cns Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cns Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.09 means the company can pay off $0.09 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cns Pharmaceuticals Inc:

  • The MRQ is 0.089. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.346. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.089TTM0.346-0.256
TTM0.346YOY4.673-4.327
TTM0.3465Y5.482-5.136
5Y5.48210Y4.782+0.700
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0893.572-3.483
TTM0.3464.001-3.655
YOY4.6735.364-0.691
5Y5.4826.009-0.527
10Y4.7826.287-1.505

1.4. Solvency of Cns Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cns Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cns Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 3.61 means that Cns Pharmaceuticals Inc assets are financed with 360.6% credit (debt) and the remaining percentage (100% - 360.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cns Pharmaceuticals Inc:

  • The MRQ is 3.606. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 2.395. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ3.606TTM2.395+1.211
TTM2.395YOY0.277+2.117
TTM2.3955Y0.685+1.710
5Y0.68510Y0.852-0.167
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6060.336+3.270
TTM2.3950.334+2.061
YOY0.2770.271+0.006
5Y0.6850.366+0.319
10Y0.8520.389+0.463
1.4.2. Debt to Equity Ratio

Measures if Cns Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cns Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cns Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.407-0.407
TTM0.407YOY0.489-0.082
TTM0.4075Y323.953-323.546
5Y323.95310Y281.698+42.255
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM0.4070.397+0.010
YOY0.4890.341+0.148
5Y323.9530.432+323.521
10Y281.6980.465+281.233

2. Market Valuation of Cns Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cns Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Cns Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.14 means the investor is paying $-0.14 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cns Pharmaceuticals Inc:

  • The EOD is -0.078. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.142. Based on the earnings, the company is expensive. -2
  • The TTM is -0.585. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.078MRQ-0.142+0.064
MRQ-0.142TTM-0.585+0.443
TTM-0.585YOY-0.514-0.071
TTM-0.5855Y-0.947+0.362
5Y-0.94710Y-0.824-0.124
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.078-2.262+2.184
MRQ-0.142-2.599+2.457
TTM-0.585-2.674+2.089
YOY-0.514-4.133+3.619
5Y-0.947-6.258+5.311
10Y-0.824-6.171+5.347
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cns Pharmaceuticals Inc:

  • The EOD is -0.165. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.301. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.862. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.165MRQ-0.301+0.135
MRQ-0.301TTM-0.862+0.561
TTM-0.862YOY-0.754-0.108
TTM-0.8625Y-1.197+0.335
5Y-1.19710Y-1.041-0.156
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.165-2.913+2.748
MRQ-0.301-3.275+2.974
TTM-0.862-3.508+2.646
YOY-0.754-5.620+4.866
5Y-1.197-8.306+7.109
10Y-1.041-8.854+7.813
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cns Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.69 means the investor is paying $-0.69 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cns Pharmaceuticals Inc:

  • The EOD is -0.379. Based on the equity, the company is expensive. -2
  • The MRQ is -0.689. Based on the equity, the company is expensive. -2
  • The TTM is -0.241. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.379MRQ-0.689+0.310
MRQ-0.689TTM-0.241-0.447
TTM-0.241YOY1.322-1.563
TTM-0.2415Y1.461-1.703
5Y1.46110Y1.271+0.191
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.3791.858-2.237
MRQ-0.6892.090-2.779
TTM-0.2412.091-2.332
YOY1.3222.866-1.544
5Y1.4613.488-2.027
10Y1.2713.836-2.565
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cns Pharmaceuticals Inc.

3.1. Institutions holding Cns Pharmaceuticals Inc

Institutions are holding 3.977% of the shares of Cns Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Armistice Capital, LLC1.44720.00211220001220000
2023-12-31Vanguard Group Inc0.692405836934604145.6091
2023-12-31Smith Anglin Financial, LLC0.59310.007350000500000
2023-12-31Geode Capital Management, LLC0.289902443600
2023-12-31State Street Corporation0.267602255600
2023-09-30FSM Wealth Advisors, LLC0.22640.01119084275016.836
2023-12-31Virtu Financial LLC0.1560.001413152131520
2023-12-31Renaissance Technologies Corp0.1322011144111440
2023-12-31XTX Topco Ltd0.11860.002810002100020
2023-12-31Tower Research Capital LLC0.04720.00013975-765-16.1392
2023-12-31FMR Inc0.002502122120
2023-12-31Wells Fargo & Co0.00250207-298-59.0099
2023-12-31Morgan Stanley - Brokerage Accounts0.000806700
2023-12-31Global Retirement Partners, LLC.0.000605300
2023-12-31Plante Moran Financial Advisors LP00100
2023-12-31Bank of America Corp001-6-85.7143
2023-12-31Susquehanna International Group, LLP000-21428-100
2023-12-31UBS Group AG000-55-100
2023-09-30Advisor Group Holdings, Inc.000-42-100
Total 3.9770.0247335259+221270+66.0%

3.2. Funds holding Cns Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.692405836900
2024-02-29Fidelity Extended Market Index0.263902224500
2024-02-29Fidelity Series Total Market Index0.05430457400
2024-02-29Fidelity Nasdaq Composite Index0.01610135800
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.0074062100
2023-12-31SSgA U.S. Extended Market Index Class I0.0071060000
2024-03-31State St US Extended Mkt Indx NL Cl C0.0071060000
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0059049910.2008
2023-12-31Northern Trust Extended Eq Market Idx0.0053045000
2023-12-31NT Ext Equity Mkt Idx Fd - L0.0053045000
2023-12-31SSgA U.S. Total Market Index Strategy0.00210173-4-2.2599
2024-02-29Spartan Extended Market Index Pool E0.000907700
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.000202000
Total 1.068090036-30.0%

3.3. Insider Transactions

Insiders are holding 5.571% of the shares of Cns Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-08-22Christopher DownsBUY270001.27
2023-08-16John M ClimacoBUY27501.8
2023-04-19Jerzy GumulkaBUY25001.7
2023-04-17Christopher DownsBUY31003.2
2023-04-12John M ClimacoBUY150000.69
2023-04-10Jerzy GumulkaBUY71730.74

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cns Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share----0.2350%-0.3350%-0.0220%-0.0230%
Book Value Per Share---0.526-0.242-54%0.935-156%0.662-179%0.566-193%
Current Ratio--0.2260.628-64%5.915-96%6.833-97%5.998-96%
Debt To Asset Ratio--3.6062.395+51%0.277+1200%0.685+426%0.852+323%
Debt To Equity Ratio---0.407-100%0.489-100%323.953-100%281.698-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.638-0.572-10%-0.446-30%-0.381-40%-0.351-45%
Free Cash Flow Per Share---0.301-0.352+17%-0.365+21%-0.306+2%-0.268-11%
Free Cash Flow To Equity Per Share---0.043-0.146+241%-0.217+408%0.051-184%0.044-197%
Gross Profit Margin--1.0001.000+0%1.000+0%1.000+0%1.000+0%
Intrinsic Value_10Y_max---7.635--------
Intrinsic Value_10Y_min---6.877--------
Intrinsic Value_1Y_max---1.380--------
Intrinsic Value_1Y_min---1.356--------
Intrinsic Value_3Y_max---3.678--------
Intrinsic Value_3Y_min---3.521--------
Intrinsic Value_5Y_max---5.410--------
Intrinsic Value_5Y_min---5.062--------
Market Cap1678464.766-82%3051754.12010542040.130-71%8133093.335-62%11580648.162-74%10070128.837-70%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio-0.379+45%-0.689-0.241-65%1.322-152%1.461-147%1.271-154%
Pe Ratio-0.078+45%-0.142-0.585+312%-0.514+262%-0.947+567%-0.824+480%
Price Per Share0.199-82%0.3621.251-71%0.965-62%1.374-74%1.195-70%
Price To Free Cash Flow Ratio-0.165+45%-0.301-0.862+187%-0.754+151%-1.197+298%-1.041+246%
Quick Ratio--0.0890.346-74%4.673-98%5.482-98%4.782-98%
Return On Assets---3.160-2.222-30%-0.432-86%-0.744-76%-1.098-65%
Return On Equity----0.4100%-0.7020%-164.0580%-142.6590%
Total Gains Per Share----0.2350%-0.3350%-0.0220%-0.0230%
Usd Book Value---4432115.000-2037637.250-54%7885441.750-156%5578374.250-179%4771830.826-193%
Usd Book Value Change Per Share----0.2350%-0.3350%-0.0220%-0.0230%
Usd Book Value Per Share---0.526-0.242-54%0.935-156%0.662-179%0.566-193%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.638-0.572-10%-0.446-30%-0.381-40%-0.351-45%
Usd Free Cash Flow---2538510.000-2964462.500+17%-3077407.500+21%-2580780.150+2%-2259187.826-11%
Usd Free Cash Flow Per Share---0.301-0.352+17%-0.365+21%-0.306+2%-0.268-11%
Usd Free Cash Flow To Equity Per Share---0.043-0.146+241%-0.217+408%0.051-184%0.044-197%
Usd Market Cap1678464.766-82%3051754.12010542040.130-71%8133093.335-62%11580648.162-74%10070128.837-70%
Usd Price Per Share0.199-82%0.3621.251-71%0.965-62%1.374-74%1.195-70%
Usd Profit---5375250.000-4823632.250-10%-4359268.750-19%-3333933.400-38%-3204995.043-40%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share----0.2350%-0.3350%-0.0220%-0.0230%
 EOD+1 -6MRQTTM+9 -15YOY+9 -155Y+7 -1710Y+4 -20

4.2. Fundamental Score

Let's check the fundamental score of Cns Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.078
Price to Book Ratio (EOD)Between0-1-0.379
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.089
Current Ratio (MRQ)Greater than10.226
Debt to Asset Ratio (MRQ)Less than13.606
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-3.160
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Cns Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.955
Ma 20Greater thanMa 500.271
Ma 50Greater thanMa 1000.310
Ma 100Greater thanMa 2000.725
OpenGreater thanClose0.205
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,701
Total Liabilities6,133
Total Stockholder Equity-4,432
 As reported
Total Liabilities 6,133
Total Stockholder Equity+ -4,432
Total Assets = 1,701

Assets

Total Assets1,701
Total Current Assets1,388
Long-term Assets313
Total Current Assets
Cash And Cash Equivalents 549
Other Current Assets 840
Total Current Assets  (as reported)1,388
Total Current Assets  (calculated)1,388
+/-0
Long-term Assets
Property Plant Equipment 5
Long-term Assets Other 308
Long-term Assets  (as reported)313
Long-term Assets  (calculated)313
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities6,133
Long-term Liabilities0
Total Stockholder Equity-4,432
Total Current Liabilities
Short-term Debt 301
Accounts payable 5,832
Total Current Liabilities  (as reported)6,133
Total Current Liabilities  (calculated)6,133
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock6
Retained Earnings -69,567
Other Stockholders Equity 65,129
Total Stockholder Equity (as reported)-4,432
Total Stockholder Equity (calculated)-4,432
+/-0
Other
Cash and Short Term Investments 549
Common Stock Shares Outstanding 5,634
Liabilities and Stockholders Equity 1,701
Net Debt -248
Net Working Capital -4,745
Short Long Term Debt Total 301



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-30
> Total Assets 
0
683
683
553
1,642
1,398
7,912
6,211
3,986
2,985
15,853
13,145
14,239
11,507
8,757
15,872
12,447
9,638
13,053
7,415
6,452
2,328
1,701
1,701
1,7011,7012,3286,4527,41513,0539,63812,44715,8728,75711,50714,23913,14515,8532,9853,9866,2117,9121,3981,6425536836830
   > Total Current Assets 
0
588
588
444
1,603
1,390
7,894
6,189
3,954
2,516
15,496
12,786
13,883
11,156
7,477
14,733
11,397
8,700
12,565
6,972
6,071
2,062
1,591
1,388
1,3881,5912,0626,0716,97212,5658,70011,39714,7337,47711,15613,88312,78615,4962,5163,9546,1897,8941,3901,6034445885880
       Cash And Cash Equivalents 
0
283
283
155
912
630
7,241
5,380
2,626
1,307
14,039
11,075
6,886
8,326
5,005
12,440
8,959
7,027
10,055
5,111
4,279
910
549
549
5495499104,2795,11110,0557,0278,95912,4405,0058,3266,88611,07514,0391,3072,6265,3807,2416309121552832830
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
133
3,702
0
0
0
0
0
0
0
0
0
0
0
000000000003,70213300000000000
       Other Current Assets 
0
272
33
269
421
456
653
809
1,329
1,209
1,456
1,579
3,296
2,830
2,473
2,293
2,439
1,673
2,509
1,862
1,792
1,152
840
840
8408401,1521,7921,8622,5091,6732,4392,2932,4732,8303,2961,5791,4561,2091,329809653456421269332720
   > Long-term Assets 
0
0
95
0
39
8
18
23
31
469
358
358
355
352
1,280
1,139
1,050
938
488
443
381
266
110
313
3131102663814434889381,0501,1391,28035235535835846931231883909500
       Property Plant Equipment 
0
0
0
0
8
8
18
23
31
28
23
24
21
18
16
13
11
9
6
4
3
3
5
5
55334691113161821242328312318880000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
334
334
334
0
0
0
0
334
0
0
0
0
0
0
00000033400003343343340000000000
       Other Assets 
0
95
95
108
31
0
0
0
0
441
334
334
334
334
1,264
1,126
1,039
929
0
0
377
0
0
0
000377009291,0391,1261,26433433433433444100003110895950
> Total Liabilities 
0
1,233
1,233
1,269
1,264
1,398
311
336
261
511
1,905
1,902
1,831
2,407
2,136
1,069
924
1,244
4,920
3,923
3,997
4,069
6,133
6,133
6,1336,1334,0693,9973,9234,9201,2449241,0692,1362,4071,8311,9021,9055112613363111,3981,2641,2691,2331,2330
   > Total Current Liabilities 
0
1,233
1,233
1,269
1,264
1,398
311
336
261
511
1,905
1,902
1,831
2,407
2,136
1,069
924
1,244
4,920
3,923
3,997
4,069
6,133
6,133
6,1336,1334,0693,9973,9234,9201,2449241,0692,1362,4071,8311,9021,9055112613363111,3981,2641,2691,2331,2330
       Short-term Debt 
0
0
317
291
300
300
300
0
0
0
439
309
178
45
388
273
156
39
410
289
166
42
0
301
301042166289410391562733884517830943900030030030029131700
       Short Long Term Debt 
0
0
0
0
300
300
0
0
0
0
439
309
178
45
388
273
156
39
410
289
166
42
301
0
030142166289410391562733884517830943900003003000000
       Accounts payable 
0
129
129
187
165
288
289
191
151
250
946
1,058
892
1,462
1,523
490
491
1,005
3,682
2,781
3,571
4,027
0
5,832
5,83204,0273,5712,7813,6821,0054914901,5231,4628921,0589462501511912892881651871291290
       Other Current Liabilities 
0
763
763
763
763
763
22
145
111
261
520
535
761
901
225
307
-428
200
828
853
260
4,027
0
0
004,027260853828200-428307225901761535520261111145227637637637637630
   > Long-term Liabilities 
0
0
446
0
465
588
289
191
151
250
1,386
1,367
1,070
1,506
1,911
762
647
1,044
4,092
3,070
0
0
0
0
00003,0704,0921,0446477621,9111,5061,0701,3671,386250151191289588465044600
       Deferred Long Term Liability 
0
95
95
108
31
0
0
0
0
441
334
334
334
334
334
334
334
334
0
0
0
0
0
0
00000033433433433433433433433444100003110895950
> Total Stockholder Equity
0
-549
-549
-717
378
0
7,601
5,875
3,725
2,474
13,948
11,243
12,408
9,100
6,622
14,803
11,523
8,394
8,133
3,492
2,454
-1,741
-4,432
-4,432
-4,432-4,432-1,7412,4543,4928,1338,39411,52314,8036,6229,10012,40811,24313,9482,4743,7255,8757,6010378-717-549-5490
   Common Stock
0
13
13
13
14
14
16
16
16
17
24
25
27
27
28
40
40
40
2
2
4
4
0
6
60442240404028272725241716161614141313130
   Retained Earnings Total Equity000000-44,7530000-28,373-24,560-20,9460000000000
   Accumulated Other Comprehensive Income 000000000000000000000000
   Capital Surplus 
0
0
0
7,093
0
8,948
19,073
19,315
0
0
34,870
35,777
40,754
0
0
0
0
53,106
0
0
0
0
0
0
00000053,106000040,75435,77734,8700019,31519,0738,94807,093000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
0
7,049
0
8,619
8,948
19,073
19,315
19,639
20,399
34,870
35,777
40,754
41,260
41,577
52,530
52,817
53,106
58,847
59,137
62,119
62,447
0
65,129
65,129062,44762,11959,13758,84753,10652,81752,53041,57741,26040,75435,77734,87020,39919,63919,31519,0738,9488,61907,04900



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-4
Gross Profit-4-4
 
Operating Income (+$)
Gross Profit-4
Operating Expense-18,861
Operating Income-18,865-18,865
 
Operating Expense (+$)
Research Development14,096
Selling General Administrative4,770
Selling And Marketing Expenses4
Operating Expense18,86118,869
 
Net Interest Income (+$)
Interest Income28
Interest Expense-14
Other Finance Cost-6
Net Interest Income7
 
Pretax Income (+$)
Operating Income-18,865
Net Interest Income7
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-18,851-18,879
EBIT - interestExpense = -18,879
-18,851
-18,837
Interest Expense14
Earnings Before Interest and Taxes (EBIT)-18,865-18,837
Earnings Before Interest and Taxes (EBITDA)-18,861
 
After tax Income (+$)
Income Before Tax-18,851
Tax Provision-0
Net Income From Continuing Ops-18,613-18,851
Net Income-18,851
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses18,865
Total Other Income/Expenses Net14-7
 

Technical Analysis of Cns Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cns Pharmaceuticals Inc. The general trend of Cns Pharmaceuticals Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cns Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cns Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.22 < 0.2484 < 0.321.

The bearish price targets are: .

Tweet this
Cns Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cns Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cns Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cns Pharmaceuticals Inc. The current macd is -0.04432507.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cns Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cns Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cns Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cns Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartCns Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cns Pharmaceuticals Inc. The current adx is 26.61.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cns Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Cns Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cns Pharmaceuticals Inc. The current sar is 0.2636041.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cns Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cns Pharmaceuticals Inc. The current rsi is 25.95. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Cns Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartCns Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cns Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cns Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cns Pharmaceuticals Inc Daily Stochastic Oscillator ChartCns Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cns Pharmaceuticals Inc. The current cci is -88.76051418.

Cns Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartCns Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cns Pharmaceuticals Inc. The current cmo is -61.29048636.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cns Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartCns Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cns Pharmaceuticals Inc. The current willr is -92.86833856.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Cns Pharmaceuticals Inc Daily Williams %R ChartCns Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cns Pharmaceuticals Inc.

Cns Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cns Pharmaceuticals Inc. The current atr is 0.03504909.

Cns Pharmaceuticals Inc Daily Average True Range (ATR) ChartCns Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cns Pharmaceuticals Inc. The current obv is 158,764,932.

Cns Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartCns Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cns Pharmaceuticals Inc. The current mfi is 21.31.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cns Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartCns Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cns Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Cns Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cns Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.955
Ma 20Greater thanMa 500.271
Ma 50Greater thanMa 1000.310
Ma 100Greater thanMa 2000.725
OpenGreater thanClose0.205
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cns Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Cns Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cns Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cns Pharmaceuticals Inc

I send you an email if I find something interesting about Cns Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cns Pharmaceuticals Inc.

Receive notifications about Cns Pharmaceuticals Inc in your mailbox!